Fred Turner

1. Key Themes

From Crisis to Durable Business: Exploiting Chaos to Build Lasting Infrastructure

Fred Turner built Curative from 7 to 7,000 employees in 9 months and $5 billion in revenue by doing what no incumbent could — treating scale as the goal from day one rather than efficiency. The key insight was that legacy lab companies were optimization machines, not scaling machines.

"The lab industry in general is a very low margin industry and it's built on efficiency... if you're asking them to 10x capacity that's literally the opposite of what they're built for." 00:28:21

He then converted roughly $500M of COVID profits into a health insurance business, avoiding the trap of assuming COVID testing would last.

"When we started hiring people at the beginning we told them this is 3 months, you have a job for 3 months, don't bank on anything beyond 3 months." 00:35:30

The Orthogonal Supply Chain: Winning Through Deliberate Non-Conformity

Rather than compete for the same consumables everyone else was chasing, Curative built an entirely separate supply chain using non-standard inputs — sourcing swabs from electronic testing vendors, substituting filter plates for magnetic beads to avoid Chinese single-source bottlenecks.

"Everybody was chasing the same consumables... if you know you can make 1x of that, maybe they can increase to make 1.2x, if everybody's trying to buy that, us also trying to buy that doesn't help... so you've got to find other ways of doing the testing using supplies that maybe wouldn't traditionally be used for this kind of testing." 00:29:26

AI Is Eliminating Entire Departments, Not Just Reducing Headcount

Fred is not talking about marginal productivity gains. Entire functions — credentialing, claims processing, underwriting intake, contract negotiation — have been restructured or zeroed out by AI agents.

"The first one that went to zero people was our credentialing department... that used to take us two to three months on average and cost about fifty dollars. We have now built in-house an agent that runs on Claude that does this end to end... we're now averaging about 12 hours turnaround time for credentialing somebody and it costs about twenty cents." 00:41:35

SaaS Is Being Replaced by Vibe-Coded Internal Tools

Curative is cutting 80% of its SaaS spend and has already cancelled a $600,000 Salesforce contract, replacing it with a vibe-coded internal CRM built in two months. The argument: custom tools built to your workflow outperform bloated general tools, and the maintenance cost of SaaS (including a full-time administrator) is no longer justified.

"We just recently cancelled our Salesforce contract because we have an internal CRM that was vibe coded that is working better, that is managing our process better, is more integrated into what we're doing... we had a full time Salesforce administrator... you can transition that into one great engineer and then whenever you want a custom feature you just go build it." 00:45:21

AI Agents Don't Just Replace Labor — They Expand Volume Exponentially

The more important realization at Curative is not cost reduction but throughput explosion. When the contracting agent "Gwen" was deployed, the team didn't keep volume flat — they multiplied it dramatically.

"Last year as an entire team we did 2,300 contracts. So far in about the last eight weeks the agent alone has done 3,500." 00:52:24

"It costs with people about $1,500 to $2,000 on average to do a contract. The average with Gwen has been about $70." 00:54:06

The Payer Is the Center of Gravity in US Healthcare

After examining hospitals, primary care chains, and lab testing, Fred concluded that none of them can drive systemic change — only the entity that controls payment can truly reshape behavior. This is why Curative became a health insurance company.

"When you come back to it... everything sort of ends up coming back to the payer. The payer is the one that drives behavior in the US healthcare system. If you are providing the dollars, people will go where the dollars are." 00:37:52

Regulatory Moats Protect AI-Enabled Incumbents in Complex Industries

Fred explicitly identifies regulated, complex industries as zones where Anthropic and OpenAI will be enablers but never competitors — creating a durable moat for well-positioned incumbents who can absorb the AI productivity gains.

"I think things that have some regulation around them and are like complex industries, yes, they're going to see the advantages of the models but they're not going to see competition from Anthropic or OpenAI." 01:08:09

Nuclear Fission's Problem Is Regulatory, Not Scientific

Fred's second company, Subcritical, is built on the thesis that nuclear energy is blocked not by engineering limitations but by regulatory constraints — and that the energy amplifier design (operating subcritically at 0.97 with particle accelerator input) solves the fundamental safety concern that drives regulation.

"We have built safe nuclear reactors since the 60s. They work great. The technology has not really changed or progressed since then. We know how to build these. That's not the problem. The problem is that due to a lot of the anti-nuclear push in the 80s, we have had a regulatory environment that has been incredibly restrictive." 01:11:42

Single-Use AI-Generated Code as a New Software Paradigm

One of the most tactically novel workflows Fred describes: agents generate Python scripts to convert any arbitrary data format into a standard format, then discard the code. No pipeline maintenance. No integration work. Just generate, use, delete.

"You can tell it to write a Python script to convert any random file into this known format and then test it and loop and iterate on your script until it's working and then you throw away that script... it's single use code that never gets used again, you just generate that code one time and then throw it away." 00:44:03

2. Contrarian Perspectives

"Agent Supervisor" Is the Most Important Job That Doesn't Exist Yet

While most of the AI labor displacement conversation focuses on what gets eliminated, Fred identifies the bottleneck no one is talking about: managing the massive volume of exceptions generated by agents running at 10x human throughput.

"Even if you're only getting an approval request 1% of the time, you're still getting 10 times as many as you were last year... how do you manage all of those exceptions that now become like a really high volume? So we've tried agents supervising agents, which I think works to a degree." 01:03:08

Anthropic Could Be Worth $10 Trillion

Against a backdrop where most analysts are arguing about whether AI valuations are in bubble territory, Fred makes a specific and extreme prediction.

"How big do you think Anthropic will be? I think it could be 10 trillion." 00:57:56

He substantiates this with the observation that developer AI spend will go from ~3.8% of salary (Mark Benioff's current figure) to 2-5x total salary within three years — implying Anthropic's revenue potential is orders of magnitude larger than current pricing suggests.

"Between maybe 2 and 5x would be the 2 and 5x salary... because I think the way we're driving workflows is that you have one senior engineer managing a bunch of downstream agents that are actually doing the work." 01:20:33

Data Cleanliness Is a False Problem — The Model Cleans It

Counter to the conventional enterprise AI wisdom that "you need clean data before you can deploy AI," Fred argues the models are already good enough to handle messy, multi-format inputs without pre-cleaning.

"I think if you approach it in the right way, then the cleanliness doesn't really matter that much because the models are so good at cleaning up the data if you give them the right context... send us whatever you've got, whatever format, it can be scribbles on a napkin, it doesn't matter, the model will figure it out." 01:01:19

The ACA's Medical Loss Ratio Cap Destroyed the Incentive to Keep People Healthy

The 85% medical loss ratio requirement sounds like consumer protection but creates a perverse incentive structure: insurers cannot benefit financially from keeping members healthy because savings flow through as lower premiums rather than retained earnings.

"85% of your premium that we collect must go out the door to pay for care... why would I encourage people to go to the gym, eat healthily if actually I'm not going to get that back anyway?" 00:48:54

The US Healthcare System Is Actually the Best in the World — If You're Sick

Against near-universal elite consensus that the US healthcare system is broken and inferior, Fred makes a direct and specific counter-claim.

"If you are sick, is the best place to be treated in the US? Yes, definitely... seriously. The US has the access to by far the most cutting edge techniques and facilities and drugs than the rest of the world and they are willing to spend a lot more in order to preserve life." 00:39:51

3. Companies Identified

Curative

Health insurance company ($1.3B valuation) that originated as a COVID testing business generating $5B revenue over three years before pivoting to become a tech-driven health insurer. Mentioned as an example of radical AI adoption eliminating entire back-office departments and deploying autonomous contracting agents.

"The total revenue ended up being about five billion over a three year period... the money that we basically put forward into the insurance business was about 500 million." 00:00:12

Anthropic

AI lab behind Claude. Curative's primary AI vendor; their Claude model powers Curative's credentialing agent, contracting agent Gwen, and other agentic workflows. Fred is dramatically bullish on their trajectory.

"Our Anthropic cost over the last six or seven months has 6x every month from a base of a couple of tens of thousands of dollars, now up to millions of dollars a month." 00:50:02

Subcritical

Nuclear fission startup co-founded by Fred Turner and his wife, based on the energy amplifier concept (subcritical operation at 0.97 using a particle accelerator to supply supplementary neutrons). Fred believes it has a larger market opportunity than Curative.

"Each one of our deployments would be about a billion dollars of construction cost for a 300 megawatt facility... it wouldn't be the same, you wouldn't raise that as equity, it would be a mix into the plant of equity and debt." 01:17:35

Y Combinator

Startup accelerator. Curative's predecessor company went through the Summer 2016 batch. Fred credits YC as the essential on-ramp that made his US startup career possible.

"I ended up going to the US for the US AgTech Investing Conference in San Francisco... I met a guy who had just finished doing Y Combinator and he was like, oh, you need to apply to YC." 00:08:15

Andreessen Horowitz (Bio Fund)

Lead investor in Fred's seed round for TL Biolabs/Shield immediately post-YC, for $1.65M. Fred notes they did not do a TAM calculation — it was a small bet on interesting technology.

"We raised a seed round from Andreessen. Their bio fund did our seed round right out of YC... it was like 1.65 million." 00:10:10

Salesforce

Mentioned as a prime example of SaaS being displaced by AI-built internal tools. Curative cancelled their $600K/year contract after vibe-coding a superior internal CRM in two months.

"We just recently cancelled our Salesforce contract because we have an internal CRM that was vibe coded that is working better." 00:45:21

Snowflake

Data platform Curative migrated to from Google Looker for dashboard visualization, at significantly lower cost. Migration was accomplished using agentic workflows rather than a large engineering team.

"We moved to do it in Snowflake and it's been a lot cheaper, it's worked really well." 01:01:19

Looker (Google)

Business intelligence tool that Curative cancelled and migrated away from as part of their 80% SaaS spend reduction.

"We moved away from Looker, right, Google's Looker product for visualizations. It's super expensive." 01:01:19

Quest Diagnostics / LabCorp

Largest incumbent US diagnostic labs, cited as examples of hyper-optimized low-margin businesses structurally incapable of scaling rapidly — which created the opening for Curative during COVID. Also used to illustrate the ceiling of the lab testing market (~$30B combined market cap).

"You look at the big labs, the Quest and LabCorps and they are ultra efficient machines... but if you're asking them to 10x capacity, that's literally the opposite of what they're built for." 00:28:21

Roche / Siemens

Large pharma/diagnostics companies that each spent hundreds of millions attempting sepsis diagnostics, failing due to the community hospital deployment problem rather than the science.

"A bunch of big pharma companies like Roche spent a couple hundred million, Siemens spent a hundred million... a bunch of companies spent a lot of money trying to make better sepsis diagnostics." 00:17:24

Wallex

Business banking company in Southeast Asia mentioned by Harry Stebbings as an example of a regulated niche where AI model providers won't compete directly.

"We're big invest in Wallex which is like business banking. Anthropic is not going into business banking in Southeast Asia." 01:08:01

4. People Identified

Co-founder and CEO of Curative, and co-founder of Subcritical. British-born, moved to Silicon Valley at 19. Previously built TL Biolabs (cattle DNA testing) and Shield (sepsis diagnostics), both through YC. Scaled Curative to $5B COVID testing revenue, then pivoted to health insurance at $1.3B valuation. Architecturally deploying AI agents across all back-office functions.

"I got kind of a taste for the speed at which you can move when everything is behind you and all the momentum is behind you, and I've been chasing that ever since." 00:05:25

Justin Mateen

Early-stage angel investor and friend of Fred Turner. Was an investor in Shield, and when that failed, invested $125,000 at a $3M valuation in the very first Curative seed round without even knowing the full business plan.

"He came in right as I was shutting down Shield... I'm thinking of starting this new thing. And he was like, yes, I'm in. And he didn't even know what it was... Put in, I think, $125,000 at a $3 million valuation." 00:19:51

Laura Deming

Longevity investor and YC alumna. Actively helped Curative in the earliest COVID days, driving Fred to LA with a car full of PCR machines and tweeting about testing capacity, which directly led to the first major LA contract.

"She tweeted, hey, we've got COVID testing capacity, does anybody want some, and the deputy mayor of LA slid into her DMs and was like, yes please, we would like to talk about that." 00:25:28

Josh Buckley

Investor and close friend of Harry Stebbings. Invested in Curative's predecessor company during the YC batch. Fred credits him as one of the first people to take a genuine bet on him as a young founder from the UK.

"Josh Buckley, who was one of the first guys who invested in us during the YC batch just because he liked what we were doing and he thought it was cool, but being willing to kind of take a bet on a kid." 01:21:38

Isaac (Curative CTO and Co-founder)

Curative's CTO and co-founder. Identified as one of the two internal leaders (alongside Fred) who moved fastest to trust and empower AI agents with real authority, including contract signing.

"Isaac, our CTO and co-founder and I have trusted the agents faster than most of the team and we're okay giving the agent authority to do things." 01:06:05

Carlo Rubbia

Nobel laureate physicist and former CERN director. Originator of the energy amplifier concept in the late 1980s/early 1990s that forms the scientific basis of Subcritical.

"It was really pushed by a guy, Carlo Rubbia, who used to be the CERN director. He was a Nobel laureate in physics... the idea is you always operate below that 1.0 threshold." 01:13:10

Josh Browder

British-born entrepreneur in Silicon Valley, mentioned by Harry as an analog to Fred (another Brit who successfully made the jump to the Valley).

"Do you know Josh Browder? He's another Brit in the Valley... Phenomenal guy." 01:09:11

Mark Benioff

Salesforce CEO, mentioned indirectly via the $600K Salesforce cancellation, and directly for the data point that Salesforce spent $300M on Anthropic, equating to ~3.8% of developer salary.

"Mark Benioff said he spent $300 million on Anthropic, equated across the developers that they have, it works out to be about 3.8% of developer salary spent on Anthropic." 01:20:12

5. Operating Insights

Relentless AI Follow-Up Outperforms Human Politeness at Scale

One of the most actionable workflow insights: human salespeople and contract teams naturally self-limit follow-up due to social discomfort. Agents have no such inhibition — and it turns out the ninth email is often what closes the deal.

"One of the things we found is that relentlessness of the follow up is what works. A lot of providers will get them on the ninth email. There is no way that a human is going to email them nine times... when you're trying to scale something up, if you can scale up that relentlessness, that is really valuable." 00:58:16

Invest in People Only Where Technical Skills or Relationships Are the Core Value

As agents consume back-office work, Fred has developed a clear two-category framework for where human headcount is retained and invested: technical skills and relationship management. Everything else is a candidate for automation.

"What we've tried to differentiate at Curative is there's two areas where we're really investing in people: that's technical skills and relationships." 00:55:17

Build the Pipeline to Match the Agent's Scale, Not the Human Team's Comfort Level

The correct response to deploying an agent that can do 10x the work is not to maintain previous volume at lower cost — it's to 10x volume and capture the market opportunity that previously wasn't addressable.

"We've not said okay we're doing 100 a week so we'll get the agent to do 100 a week. What we've done is said well now that we have the agent we can do 10 times as many contracts this year as we could do last year, so we're going to do 10 times and we're going to do 20 times." 00:54:30

Pay Creditors and Investors Before Reinvesting — Create Loyalty Capital

Curative paid investors 10x their money back via dividend before pivoting to insurance, and the investors still retained their equity. This created an extraordinarily loyal investor base that led the next $150M round.

"We paid out some, all the investors got 10x their money back before we started the health insurance company and then they still had their shares today... this last round was led by insiders." 01:08:30

Use a Lost Deal as an Existential Forcing Function

Fred's first company Shield died when a strategic investor killed a Series B term sheet after three weeks of diligence. Rather than treating this as catastrophe, he reframes near-death experiences as reorientation events — and notes the company wouldn't have pivoted hard enough into COVID without it.

"Would you be where you are today though if that round had come together? No... I don't think we would have pivoted as hard into COVID when COVID hit." 00:15:20

6. Overlooked Insights

The CLIA Lab License as a Hidden Regulatory Moat Worth Orders of Magnitude More in a Crisis

Fred sold Curative's CLIA lab license for $150,000 during the wind-down of Shield in December 2019 — then five months later paid $27 million to acquire a comparable license for the COVID business. This throwaway detail reveals a profound truth about regulatory licenses in healthcare: their value is not intrinsic, it is context-dependent, and in a crisis they become lottery tickets. Any investor or operator in diagnostics, lab testing, or adjacent regulated healthcare should note that these licenses may be sitting on portfolios at book value with enormous option value in a future health emergency.

"In December of 2019, as part of the wind down, I sold that license to a company in San Diego for $150,000 to pay some of the creditors. And then five months later, acquired a company in Southern California to get the same license for 27 million." 00:15:24

Gwen the Contracting Agent Is a Template for Entire Industry Transformation — Not Just Insurance

Fred describes Gwen doing 3,500 contracts in 8 weeks vs. 2,300 in a full prior year by an entire human team, at $70 per contract vs. $1,500–$2,000, sending 15,000 customized emails per day, negotiating multi-round terms, redlining agreements, and executing DocuSign. This is not a productivity tool — it is a complete replacement of a commercial function that every company in every regulated industry must perform. The implication goes far beyond insurance: any industry where bilateral contracting at scale is a barrier to network building (telecom, banking, real estate, logistics) faces the same disruption vector. The companies that deploy this first will build network density that took incumbents 50–100 years to accumulate, in years.

"Last year as an entire team we did 2,300 contracts. So far in about the last eight weeks the agent alone has done 3,500... it costs with people about $1,500 to $2,000 on average to do a contract. The average with Gwen has been about $70." 00:52:24